BIOMAT Database Logo BIOMAT Database Logo

Insulin patents and market exclusivities: unresolved issues--Authors' reply. 2016

Jing Luo, and Aaron S Kesselheim
Program On Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. Electronic address: jluo1@partners.org.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016568 Drugs, Generic Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies. Drugs, Nonproprietary,Generic Drug,Generic Drugs,Drug, Generic,Nonproprietary Drugs

Related Publications

Jing Luo, and Aaron S Kesselheim
Insulin patents and market exclusivities: unresolved issues.
February 2016, The lancet. Diabetes & endocrinology,
Jing Luo, and Aaron S Kesselheim
Brexit and UK market exclusivities.
March 2018, Pharmaceutical patent analyst,
Jing Luo, and Aaron S Kesselheim
Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
January 2015, PloS one,
Jing Luo, and Aaron S Kesselheim
Market Share: The Authors Reply.
May 2017, Health affairs (Project Hope),
Jing Luo, and Aaron S Kesselheim
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
August 2023, JAMA,
Jing Luo, and Aaron S Kesselheim
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
November 2023, PLoS medicine,
Jing Luo, and Aaron S Kesselheim
Catheter interventions: an unresolved clinical controversy - Authors' reply.
March 2020, The Lancet. Haematology,
Jing Luo, and Aaron S Kesselheim
The Individual Market: The Authors Reply.
May 2020, Health affairs (Project Hope),
Jing Luo, and Aaron S Kesselheim
Biologics, Patents and Regulatory Exclusivities: Incentivising the Development of Future Pharmaceuticals.
June 2022, Journal of law and medicine,
Jing Luo, and Aaron S Kesselheim
Endo/epicardial mapping issues: Authors' reply.
September 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Copied contents to your clipboard!